Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024316 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
A Phase 1 study of Congenital Erythropoietic Porphyria (CEP), sponsored by Atlas Molecular Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT07024316: Recruiting Phase 1 study of Congenital Erythropoietic Porphyria (CEP), sponsored by Atlas Molecular Pharma.
NCT07024316 is a Phase 1 study of Congenital Erythropoietic Porphyria (CEP) that is actively recruiting participants, run by Atlas Molecular Pharma. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024316, a Phase 1 study of Congenital Erythropoietic Porphyria (CEP), is actively recruiting participants, sponsored by Atlas Molecular Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
Primary Outcome
Change between 6-month run-in period and 12-weekly treatment intervals in number and severity of sunlight-induced events measured with the Dermatological Sunlight Questionnaire (DSQ) on a daily basis: * Number of lesions * Average time to recovery of lesions * Number of other symptoms and clinical signs
Conditions Studied
Interventions
- DRUG ATL-001 (Ciclopirox oral solution)
Study Locations (1)
Ohio
- The Cleveland Clinics - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 1 |
What NCT07024316 shows while recruiting
NCT07024316 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Congenital Erythropoietic Porphyria (CEP) appearing as the primary indexed condition, and to 1 intervention - of which ATL-001 (Ciclopirox oral solution) is the first listed.
NCT07024316 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07024316 about?
NCT07024316 is a clinical study titled "A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP". This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
What is the current status of trial NCT07024316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2026-01-15. Estimated completion is 2027-11-01.
What conditions does trial NCT07024316 study?
This clinical trial studies the following conditions: Congenital Erythropoietic Porphyria (CEP).
What interventions are being tested in trial NCT07024316?
The interventions under investigation include: ATL-001 (Ciclopirox oral solution) (DRUG).
Who is sponsoring clinical trial NCT07024316?
This trial is sponsored by Atlas Molecular Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024316 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07024316's enrollment target sits among peer trials
6 1975th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI